Aiming to brush last year's flop aside, Fulcrum sees shares skyrocket on early look at sickle cell program
Fulcrum Therapeutics $FULC is looking to rebound after the Phase II flop of an old GlaxoSmithKline drug slashed their market value in half last August. And if Tuesday’s stock movement is any indication, investors like what they see.
At an interim analysis of a Phase I study, Fulcrum reported that their program designed to treat inherited blood disorders hit a statistically significant rate in two key measurements, the company announced Tuesday morning. The results sent Fulcrum shares skyrocketing more than 125%, sending the stock price back above what it had been before last year’s whiff.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.